{
  "id": 13237826,
  "title": "ME Therapeutics Extends Option Agreement for CD22 Nanobody Asset",
  "url": "https://urgent.news/2026/10/09/me-therapeutics-extends-option-agreement-for-cd22-nanobody-asset",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-09T22:35:50.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/me-therapeutics-extends-option-agreement-for-cd22-nanobody-asset"
  },
  "original_language": "en",
  "account": null,
  "summary": "VANCOUVER, British Columbia — ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer-fighting drugs in the field of immuno-oncology, today announced an extension to its option agreement to license the National Research Council of Canada’s (NRC) proprietary nanobody-based CD22 binder for use […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}